Predicting Recurrence in HR+/HER2- Early Breast Cancer
NCT07484763
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
500
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer, HR+/HER2- Early-Stage
Sponsor
Shengjing Hospital